DA-8010

DRUG2 trials

Sponsors

Dong-A ST Co., Ltd.

Conditions

HealthyOveractive BladderRenal Impairment

Phase 1

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects

Dong-A ST Co., Ltd.Overactive Bladder

Start: 2016-06-30End: 2017-04-30Target: 110Updated: 2016-07-01

A Study to Evaluate the Effects of Renal Function on Pharmacokinetics and Safety of DA-8010

CompletedNCT05812417

Dong-A ST Co., Ltd.Healthy, Renal Impairment

Start: 2023-05-02End: 2024-06-07Updated: 2024-06-26

Related Papers

Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 Study

International Neurourology Journal2022-06-299 citations